- Home
- ESEA vs NKTX Comparison
ESEA vs NKTX Comparison
Compare ESEA & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESEA
- NKTX
- Stock Information
- Founded
- ESEA 2005
- NKTX 2015
- Country
- ESEA Greece
- NKTX United States
- Employees
- ESEA N/A
- NKTX N/A
- Industry
- ESEA Marine Transportation
- NKTX Biotechnology: Pharmaceutical Preparations
- Sector
- ESEA Consumer Discretionary
- NKTX Health Care
- Exchange
- ESEA Nasdaq
- NKTX Nasdaq
- Market Cap
- ESEA 432.8M
- NKTX 123.5M
- IPO Year
- ESEA 2006
- NKTX 2020
- Fundamental
- Price
- ESEA $63.57
- NKTX $1.91
- Analyst Decision
- ESEA Strong Buy
- NKTX Strong Buy
- Analyst Count
- ESEA 1
- NKTX 5
- Target Price
- ESEA $62.00
- NKTX $13.50
- AVG Volume (30 Days)
- ESEA 41.9K
- NKTX 489.9K
- Earning Date
- ESEA 08-13-2025
- NKTX 11-06-2025
- Dividend Yield
- ESEA 4.44%
- NKTX N/A
- EPS Growth
- ESEA 0.63
- NKTX N/A
- EPS
- ESEA 17.09
- NKTX N/A
- Revenue
- ESEA $221,034,167.00
- NKTX N/A
- Revenue This Year
- ESEA $9.61
- NKTX N/A
- Revenue Next Year
- ESEA $1.86
- NKTX N/A
- P/E Ratio
- ESEA $3.62
- NKTX N/A
- Revenue Growth
- ESEA 7.73
- NKTX N/A
- 52 Week Low
- ESEA $24.58
- NKTX $1.31
- 52 Week High
- ESEA $65.50
- NKTX $5.83
- Technical
- Relative Strength Index (RSI)
- ESEA 60.68
- NKTX 38.03
- Support Level
- ESEA $61.67
- NKTX $2.00
- Resistance Level
- ESEA $64.99
- NKTX $2.08
- Average True Range (ATR)
- ESEA 2.10
- NKTX 0.11
- MACD
- ESEA -0.39
- NKTX -0.03
- Stochastic Oscillator
- ESEA 74.60
- NKTX 0.00
About ESEA Euroseas Ltd. (Marshall Islands)
Euroseas Ltd is a shipping company. Its fleet consists of containerships that transport container boxes, providing scheduled service between ports. Its operations are managed by an affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. The company employs its vessels on spot and period charters and through pool arrangements.
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.